- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01221740
Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
- To show that patients with greater pain sensitivity will show greater improvement in their symptoms (self-reported pain intensity, mood, sleep, and quality of life) than those with lower pain sensitivity, based on QST, after taking milnacipran.
- To compare outcome differences (pain intensity, mood, activity interference, sleep, and side effects) with those patients who are either taking or not taking opioids for their pain 10 weeks after being prescribed milnacipran.
- To show that patients who are older, male, with more medical comorbidities, greater disability, and longer pain duration will report less improvement (pain, mood, sleep, health-related quality of life) and treatment satisfaction while taking milnacipran compared with others without such characteristics.
Study Overview
Detailed Description
Chronic pain is a costly syndrome that influences every aspect of a patient's life. Significant interference with sleep, employment, social functioning, and daily activities is common. Chronic pain patients frequently report depression, anxiety, irritability, sexual dysfunction, and decreased energy. Family roles are altered, and worries abound about financial limitations and future consequences of a restricted lifestyle. Epidemiological studies have independently documented that chronic pain is an immense international problem. Chronic pain symptoms afflict one third of the American population (more than 80 million people). Chronic pain accounts for 21% of emergency room visits and 25% of annual missed work days. When direct and indirect costs are considered, chronic pain imposes a greater economic burden than any other disease, with annual estimates up to $100 billion.
Patients will complete a number of questionnaires at baseline and undergo quantitative sensory testing (QST) as well as complete a handheld electronic diary PDA throughout the entire 10 weeks of the study. Patients will be evaluated by a physician and receive a complete history and physical. Radiological studies will be consulted to confirm diagnosis. All subjects who consent to participate in this study will be started on or converted to milnacipran if they are currently taking an SSRI, buproprion, or a TCA. This will be done over a 1 to 2 week period of gradually weaning the antidepressant and escalating milnacipran. All other adjuvant medication will remain constant through the course of the 10-week trial. Efforts will be made to recruit at least 40% of the patients (N= 24) who are not taking opioids for pain.
At the end of the study, all patients will repeat the baseline questionnaires listed above except the demographic questionnaire. They will also be asked to complete the Treatment Helpfulness Questionnaire. We will compare secondary outcome differences (treatment satisfaction and helpfulness) between patients either on or off of opioids.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Chestnut Hill, Massachusetts, United States, 02467
- Brigham and Women's Hospital Pain Trials Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Primary diagnosis of spinal pain for at least 6 months' duration
- Average pain intensity score of 4 or greater
Exclusion Criteria:
- Current diagnosis of cancer or malignant disease
- Acute bone disease
- History of DSM-IV psychotic disorder
- Pregnancy
- Any illness judged by the PI to interfere with treatment
- Any acute condition requiring surgery
- Currently taking SNRI or MAOI
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Milnacipran
The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period. 12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8 |
The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks. 12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Decreased Back Pain
Time Frame: Over the course of 10 weeks
|
Decreased Back Pain on the Brief Pain Inventory Scale.
|
Over the course of 10 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- age
- sleep
- pain intensity
- mood
- side effects
- QST
- gender
- activity
- milnacipran
- interference
- To show that patients with greater pain sensitivity
- will show greater improvement in their symptoms
- (self-reported pain intensity, mood, sleep, and
- quality of life) than those with lower pain
- sensitivity, based on QST, after taking milnacipran.
- To compare outcome differences
- (pain intensity, mood, activity interference,
- sleep, and side effects) with those patients
- who are either taking or not taking opioids for
- their pain 10 weeks after being prescribed milnacipran.
- To show that patients who are older, male,
- with more medical comorbidities, greater disability,
- and longer pain duration will report less improvement
- (pain, mood, sleep, health-related quality of life)
- and treatment satisfaction while taking milnacipran
- compared with others without such characteristics.
- identify patients back or neck pain
- greater 6 months
- 10 weeks
- medical comorbidities
- pain diagnosis
- pain duration
- disability status
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Back Pain
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Psychotropic Drugs
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Antidepressive Agents
- Serotonin and Noradrenaline Reuptake Inhibitors
- Milnacipran
- Levomilnacipran
Other Study ID Numbers
- 2010-P-00977/1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Back Pain
-
Dow University of Health SciencesRecruitingLow Back Pain | Chronic Low-back Pain | Low Back Pain, Mechanical | Mechanical Low Back Pain | Pain, Chronic | Pain, Back | Lower Back Pain Chronic | CLBP - Chronic Low Back PainPakistan
-
Faculdade de Ciências Médicas da Santa Casa de...CompletedLow Back Pain, Mechanical | Low Back Pain, Postural | Lower Back Pain Chronic | Low Back Pain, Posterior CompartmentBrazil
-
Federal University of Minas GeraisRecruitingBack Pain | Low Back Pain | Chronic Low-back Pain | Back Pain Lower Back ChronicBrazil
-
University of Colorado, BoulderNational Institutes of Health (NIH); Radiological Society of North America; Psychophysiologic... and other collaboratorsCompletedChronic Pain | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Marco LoggiaNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingLow Back Pain | Pain, Chronic | Back Pain Lower Back Chronic | Back Pain With Radiation | Back Pain Without Radiation | Back AcheUnited States
-
Carilion ClinicVirginia Center for Health InnovationEnrolling by invitationBack Pain | Back Pain Lower Back Chronic | Back Pain, LowUnited States
-
Canandaigua VA Medical CenterFoot Levelers, Inc.; Northeast College of Health SciencesTerminatedBack Pain Lower Back ChronicUnited States
-
Balgrist University HospitalUniversity of Zurich, Epidemiology, Biostatistics and Prevention InstituteCompletedBack Pain | Back Pain With Radiation | Back Pain, LowSwitzerland
-
Vanderbilt University Medical CenterWithdrawnBack Pain, Low | Back Pain Without RadiationUnited States
-
Columbia UniversityUpright Technologies Ltd.CompletedLower Back Pain | Back Pain | Postural Low Back PainUnited States
Clinical Trials on Savella
-
Banner HealthForest LaboratoriesTerminatedFibromyalgiaUnited States
-
Beth Israel Medical CenterCompleted
-
Brigham and Women's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedArthritis, RheumatoidUnited States
-
Northwestern UniversityForest Laboratories; Shirley Ryan AbilityLab; Best PracticeCompleted
-
Forest LaboratoriesCypress Bioscience, Inc.CompletedFibromyalgiaUnited States
-
University of California, San DiegoForest Laboratories; US Department of Veterans AffairsCompleted
-
Montefiore Medical CenterForest LaboratoriesCompletedAutism Spectrum Disorder | Asperger Syndrome | Aspergers SyndromeUnited States
-
Forest LaboratoriesCypress Bioscience, Inc.TerminatedPrimary FibromyalgiaUnited States
-
Spencer Dorn, MD, MPHForest LaboratoriesTerminated
-
University of TennesseeForest LaboratoriesCompleted